#1 Clinical Trials Search in Europe

Dexamethasone Isonicotinate

This article discusses recent clinical trials investigating the use of Dexamethasone Isonicotinate in treating various forms of B-cell lymphoma. These studies aim to evaluate the safety and efficacy of this drug when combined with other treatments for patients with different types of lymphoma, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

Table of Contents

What is Dexamethasone Isonicotinate?

Dexamethasone Isonicotinate is a corticosteroid medication that is being studied for its potential use in treating various medical conditions, particularly in the field of oncology[1]. It is a specific form of dexamethasone, which is a well-known and widely used anti-inflammatory and immunosuppressant drug.

Medical Conditions Treated

Based on the clinical trial information provided, Dexamethasone Isonicotinate is being investigated for its potential use in treating:

  • B-cell Non-Hodgkin Lymphoma (NHL): This is a type of cancer that affects the lymphatic system, particularly the B-cells, which are a type of white blood cell[1].
  • Diffuse Large B-cell Lymphoma (DLBCL): This is the most common type of NHL, characterized by rapidly growing abnormal B-cells[2].
  • Follicular Lymphoma (FL): Another type of NHL that typically grows slowly[1].

How It Works

Dexamethasone Isonicotinate, like other corticosteroids, works by suppressing the immune system and reducing inflammation in the body. In the context of lymphoma treatment, it may help in several ways:

  • Reducing inflammation associated with cancer
  • Alleviating symptoms caused by the cancer or other treatments
  • Potentially enhancing the effects of other cancer treatments

Administration and Dosage

According to the clinical trial information, Dexamethasone Isonicotinate can be administered in different ways:

  • Intravenous (IV): Given directly into a vein[1].
  • Oral: Taken by mouth in tablet or liquid form[2].

The dosage may vary depending on the specific condition being treated and the individual patient. In one of the trials, the maximum daily dose was reported as 15 mg, with a maximum total dose of 240 mg over a treatment period of up to 16 weeks[2]. However, it’s important to note that these dosages are specific to the clinical trial and may not represent standard treatment regimens.

Clinical Trials and Research

Dexamethasone Isonicotinate is currently being studied in clinical trials, often in combination with other medications. Some key points about these trials include:

  • It’s being tested in combination with various chemotherapy regimens for different types of lymphoma[1].
  • The drug is part of treatment protocols for both newly diagnosed and relapsed/refractory (R/R) lymphoma patients[2].
  • Researchers are evaluating its efficacy, safety, and tolerability when used alongside other cancer treatments[1][2].

Potential Side Effects

While the specific side effects of Dexamethasone Isonicotinate are still being studied, corticosteroids like dexamethasone can generally cause:

  • Increased appetite and weight gain
  • Mood changes
  • Difficulty sleeping
  • Increased blood sugar levels
  • Weakened immune system
  • Changes in skin (thinning, easy bruising)

The clinical trials are closely monitoring for adverse events and changes in laboratory values to better understand the safety profile of this medication[1][2].

Precautions and Contraindications

Based on the clinical trial information, certain precautions and contraindications for the use of Dexamethasone Isonicotinate in combination with other treatments include:

  • Patients with active infections, including tuberculosis, should not receive this treatment[1][2].
  • Those with a history of severe allergic reactions to anti-CD20 antibody therapy may not be eligible[2].
  • Patients with certain cardiovascular diseases or uncontrolled concomitant diseases may be excluded from treatment[1][2].
  • Pregnancy and breastfeeding are contraindications, and patients are required to use effective contraception during and after treatment[1][2].

It’s crucial to discuss all medical conditions, medications, and concerns with your healthcare provider before considering treatment with Dexamethasone Isonicotinate or participating in related clinical trials.

Aspect Details
Drug Name Dexamethasone Isonicotinate
Drug Class Corticosteroid
Administration Intravenous or Oral
Maximum Daily Dose 15 mg
Maximum Total Dose 240 mg
Treatment Duration Up to 16 weeks
Target Conditions B-cell lymphomas (DLBCL, FL, and other subtypes)
Trial Phases Phase 1b/2 and Phase 3
Primary Objectives Evaluate safety, tolerability, and efficacy
Key Endpoints Overall survival, progression-free survival, response rates

FAQ

  • What is Dexamethasone Isonicotinate? Dexamethasone Isonicotinate is a corticosteroid medication used in combination with other drugs to treat various types of B-cell lymphomas. It helps reduce inflammation and suppress the immune system, which can be beneficial in managing lymphoma symptoms and enhancing the effectiveness of other treatments.
  • What types of lymphoma are being studied in these trials? The clinical trials are focusing on different types of B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other subtypes such as T-cell/histiocyte-rich large B-cell lymphoma and 'double-hit' or 'triple-hit' DLBCL.
  • How is Dexamethasone Isonicotinate administered in these trials? In the trials, Dexamethasone Isonicotinate is administered either intravenously or orally, depending on the specific treatment regimen. The maximum daily dose is 15 mg, with a maximum total dose of 240 mg over a treatment period of up to 16 weeks.
  • What are the main objectives of these clinical trials? The main objectives of these trials are to assess the safety, tolerability, and efficacy of Dexamethasone Isonicotinate when used in combination with other drugs for treating B-cell lymphomas. They also aim to evaluate factors such as overall survival, progression-free survival, and response rates to the treatment.
  • Who is eligible to participate in these clinical trials? Eligibility criteria vary between trials but generally include adults (18 years or older) with confirmed B-cell lymphoma diagnoses, measurable disease, and adequate organ function. Patients must also meet specific criteria related to their disease status, previous treatments, and overall health condition.

Ongoing Clinical Trials on Dexamethasone Isonicotinate

  • Study Comparing Epcoritamab with Chemotherapy for Patients with Relapsed or Refractory B-cell Lymphoma

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Denmark Finland France Germany +7

  • Study on the Safety and Effectiveness of Epcoritamab with a Drug Combination for Patients with B-cell Non-Hodgkin Lymphoma

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Czechia Denmark Finland France Italy +4

Glossary

  • B-cell lymphoma: A type of cancer that affects B lymphocytes, a kind of white blood cell that plays a crucial role in the immune system.
  • Diffuse large B-cell lymphoma (DLBCL): The most common type of non-Hodgkin lymphoma, characterized by rapidly growing abnormal B-cells in lymph nodes or other organs.
  • Follicular lymphoma (FL): A slow-growing type of non-Hodgkin lymphoma that develops from B-cells and typically occurs in the lymph nodes.
  • Corticosteroid: A class of steroid hormones produced naturally in the body or synthesized for medical use, often used to reduce inflammation and suppress the immune system.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with the disease without it worsening.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Response rate: The percentage of patients whose cancer shrinks or disappears after treatment.
  • Autologous stem cell transplant (ASCT): A procedure where a patient's own stem cells are collected, stored, and then reinfused after high-dose chemotherapy to help restore the bone marrow.
  • Minimal residual disease (MRD): The small number of cancer cells that remain in the body during or after treatment, often undetectable through standard tests.
  • Lugano criteria: A set of standardized guidelines used to evaluate response to treatment in lymphoma patients.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-epcoritamab-with-a-drug-combination-for-patients-with-b-cell-non-hodgkin-lymphoma/
  2. http://clinicaltrials.eu/trial/study-comparing-epcoritamab-with-chemotherapy-for-patients-with-relapsed-or-refractory-b-cell-lymphoma/